X Pivot

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi A retrospective study of first indicators of breast cancer recurrence
    X Pivot
    Centre Antoine Lacassagne, Nice, France
    Oncology 58:185-90. 2000
  2. ncbi Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck
    X Pivot
    Centre Antoine Lacassagne, Nice, France
    Oncology 60:66-71. 2001
  3. ncbi Primary lung sarcomas: long survivors obtained with iterative complete surgery
    N Magne
    Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice Cedex 2, France
    Lung Cancer 31:241-5. 2001
  4. ncbi Clinical prognostic factors for patients with recurrent head and neck cancer: implications for randomized trials
    X Pivot
    Centre Antoine Lacassagne, Nice, France
    Oncology 61:197-204. 2001
  5. ncbi Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study
    R J Bensadoun
    Department of Radiation Oncology, Centre Antoine Lacassagne, Nice, France
    Int J Radiat Oncol Biol Phys 42:237-45. 1998
  6. pmc A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil
    M C Etienne
    Centre Antoine Lacassagne, Nice, France
    Br J Cancer 79:1864-9. 1999
  7. ncbi Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients: A long-term quality of life analysis
    N Magne
    Department of Head and Neck Oncology, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice Cedex 2, France
    Head Neck 23:678-82. 2001
  8. ncbi Liver metastases from head and neck squamous cell carcinomas: radiological and biological features
    P Y Marcy
    Department of Radiology, Centre Antoine Lacassagne, Nice, France
    Onkologie 27:157-60. 2004
  9. ncbi The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy
    N Magne
    Department of Radiotherapy, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice Cedex 2, France
    Eur J Cancer 37:2169-77. 2001
  10. ncbi [Concomitant bifractionated radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in locally progressive, non-resectable epidermoid carcinomas of the pharynx: ten years experience at the Antoine Lacassagne center]
    N Magne
    Centre Antoine Lacassagne, 33, Avenue de Valombrose, 06189 Nice, France
    Cancer Radiother 5:413-24. 2001

Collaborators

Detail Information

Publications16

  1. ncbi A retrospective study of first indicators of breast cancer recurrence
    X Pivot
    Centre Antoine Lacassagne, Nice, France
    Oncology 58:185-90. 2000
    ..In addition, early detection of metastases would be even more valuable if more effective treatment modalities of recurrent or metastatic breast cancer were available...
  2. ncbi Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck
    X Pivot
    Centre Antoine Lacassagne, Nice, France
    Oncology 60:66-71. 2001
    ..Twenty-seven patients with recurrent squamous cell carcinoma of the head and neck were entered in a multicenter study to determine the efficacy of the paclitaxel-carboplatin association...
  3. ncbi Primary lung sarcomas: long survivors obtained with iterative complete surgery
    N Magne
    Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice Cedex 2, France
    Lung Cancer 31:241-5. 2001
    ..Because no specific symptom was linked with the local relapse, a systematic CT scan every 2 or 3 months could be required...
  4. ncbi Clinical prognostic factors for patients with recurrent head and neck cancer: implications for randomized trials
    X Pivot
    Centre Antoine Lacassagne, Nice, France
    Oncology 61:197-204. 2001
    ..The advantages of taking into account such prognostic factors are to eliminate the patient selection bias and to ensure a fairer comparative evaluation of new or already existing agents in recurrent head and neck cancer...
  5. ncbi Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study
    R J Bensadoun
    Department of Radiation Oncology, Centre Antoine Lacassagne, Nice, France
    Int J Radiat Oncol Biol Phys 42:237-45. 1998
    ..i.d.) continuous nonaccelerated radiotherapy with concomitant cisplatin (CP)-5-fluorouracil (5-FU) chemotherapy, both given at full dose. Feasibility, efficacy, survival, and pharmacokinetic-pharmacodynamic relationships were analyzed...
  6. pmc A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil
    M C Etienne
    Centre Antoine Lacassagne, Nice, France
    Br J Cancer 79:1864-9. 1999
    ..68 for T staging and 2.65 for EGFR. Overall, EGFR remained an independent prognostic factor when response to treatment and T staging were considered in the multivariate analysis...
  7. ncbi Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients: A long-term quality of life analysis
    N Magne
    Department of Head and Neck Oncology, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice Cedex 2, France
    Head Neck 23:678-82. 2001
    ....
  8. ncbi Liver metastases from head and neck squamous cell carcinomas: radiological and biological features
    P Y Marcy
    Department of Radiology, Centre Antoine Lacassagne, Nice, France
    Onkologie 27:157-60. 2004
    ....
  9. ncbi The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy
    N Magne
    Department of Radiotherapy, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice Cedex 2, France
    Eur J Cancer 37:2169-77. 2001
    ..EGFR determination appears to be a powerful prognostic parameter in unresectable pharyngeal cancer patients treated by concomitant chemo-radiotherapy...
  10. ncbi [Concomitant bifractionated radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in locally progressive, non-resectable epidermoid carcinomas of the pharynx: ten years experience at the Antoine Lacassagne center]
    N Magne
    Centre Antoine Lacassagne, 33, Avenue de Valombrose, 06189 Nice, France
    Cancer Radiother 5:413-24. 2001
    ..Evaluation was based on analysis of the toxicity, the response rates, the survival, and the clinical prognostic factors...
  11. ncbi Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site: a phase II trial
    E Guardiola
    Centre Antoine Lacassagne, Nice, France
    Am J Clin Oncol 24:372-5. 2001
    ..However, the emergence of long-term survivors among responder patients highlighted the need to search for an active treatment for patients with ACUP...
  12. ncbi Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer
    X Pivot
    Centre Antoine Lacassagne, Nice, France
    Ann Oncol 12:1595-9. 2001
    ..3% and 10.8% of objective responses, 1.9 versus 1.5 months of disease-free progression and 3.5 versus 3.7 months of overall survival, respectively. Nolatrexed has demonstrated a similar activity to methotrexate...
  13. doi Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy
    F C Bidard
    CirCe laboratory, Centre Antoine Lacassagne, France
    Ann Oncol 21:1765-71. 2010
    ..We investigated whether circulating tumor cells (CTCs) and circulating endothelial cells (CECs) predict clinical outcome of first-line chemotherapy combined with bevacizumab in metastatic breast cancer patients...
  14. pmc Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
    X Pivot
    Centre Antoine Lacassagne, Nice, France
    Br J Cancer 85:649-55. 2001
    ..Although substantial haematological toxicities were experienced by patients, subsequent studies have shown that these toxicities can be proactively managed by folic acid and vitamin B(12)supplementation...
  15. ncbi Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance
    M C Etienne
    Centre Antoine Lacassagne, Nice, France
    Ann Oncol 14:643-7. 2003
    ....
  16. pmc A unified definition of clinical anthracycline resistance breast cancer
    X Pivot
    Centre Antoine Lacassagne, Nice, France
    Br J Cancer 82:529-34. 2000
    ..The definitions used in Groups 3 and 4 include many patients with responsive tumours, and a more favourable prognosis...